Recurrent glioblastoma in the era of molecular diagnostics: practice variation and practical implications

Abstract

The journey of a patient with recurrent glioblastoma is subject to practice variation in diagnostics and treatments, in which the clinical implementation of WGS results in the context of precision oncology has currently little support from treating physicians, accompanied by some ethical objections that need to be considered. Another important conclusion is that routine WGS-based diagnostics might help the (future) patient, since WGS - which was proven fast and feasible in our population - has a great potential to not only create a lot of new knowledge about the biology of glioblastomas, but also to unravel novel targets for treatment.